Delivery of Anti-miRNA for Triple Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting to Stem Cell Marker CD133

Molecular Therapy - United States
doi 10.1016/j.ymthe.2019.04.018
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Dasatinib Sensitises Triple Negative Breast Cancer Cells to Chemotherapy by Targeting Breast Cancer Stem Cells

British Journal of Cancer
Cancer ResearchOncology
2018English

Targeting Stromal Remodeling and Cancer Stem Cell Plasticity Overcomes Chemoresistance in Triple Negative Breast Cancer

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2018English

CD133 in Breast Cancer Cells: More Than a Stem Cell Marker

Journal of Oncology
Oncology
2019English

Targeting MYC for Triple-Negative Breast Cancer Treatment

Oncoscience
Cancer ResearchOncology
2018English

Targeting DNA Methylation for Treating Triple-Negative Breast Cancer

Pharmacogenomics
Molecular MedicineGeneticsPharmacology
2019English

Nano-Targeted Delivery of Rad6/Translesion Synthesis Inhibitor for Triple Negative Breast Cancer Therapy

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

Detection of miRNA Regulatory Effect on Triple Negative Breast Cancer Transcriptome

BMC Genomics
BiotechnologyGenetics
2015English

Development of a Vaccine Targeting Triple-Negative Breast Cancer

2013English

Cetuximab-Conjugates Nanoparticles for the Treatment of Triple Negative Breast Cancer

2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy